Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 6;5(12):e397. doi: 10.1038/mtna.2016.105

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

IDO shRNA and D-1MT treatment induced Th1-bias immune responses. Spleens were collected at 16 days after LLC1 injection. Splenocytes and culture medium were collected after 24 hours culture. (a) mRNA expression of IDO. (b) mRNA expression of IFN-γ and IL-10. (c) Cytokines concentration of IFN-γ, TNF-α, IL-4 and IL-10. * or **A statistically significant difference when compared with scramble IDO shRNA group (*P < 0.05; **P < 0.01). D-1MT, 1-methyl-D-tryptophan; IDO, Indoleamine 2,3-dioxygenase; IFN-γ, interferon- γ; IL-4, interlukein-4; shRNA, short hairpin RNA; TNF-α, tumor necrosis factor- α.